Regional Academic Conferences Spotlight | Tri-Region Collaboration Empowers Digital Pathology with AI
Dipath
AI-Assisted Diagnostic Tool Developer
Recently, a series of academic conferences in the field of regional pathology have been held successively, with Dipath making consecutive appearances.The 24th Cytopathology Conference of the Chinese Medical Association、2026 Annual Academic Conference of the Pathology Branch, Xinjiang Medical Association、The 12th Hangzhou Breast Cancer Forum (Hangzhou Conference) and Zhejiang Provincial Breast Cancer Screening Training ConferenceThree Major Industry Conferences: Showcasing Cutting-Edge AI Technology, a Comprehensive Portfolio of Digital Intelligence Pathology Products, and Proven Clinical Implementation Achievements; Engaging in In-Depth Exchanges with Pathology Experts and Clinicians Across China to Empower Industry Development Through Technology and Support Frontline Healthcare Professionals with Care.
Dipath’s full suite of digital-intelligent pathology solutions was simultaneously showcased at two venues: the 24th Conference on Cytopathology of the Chinese Medical Association and the 2026 Annual Academic Conference of the Pathology Branch of the Xinjiang Medical Association.The entire product series is built on DeepPathAI’s self-developed foundational large model for pathology.，With robust in-house R&D capabilities and high practical value tailored to clinical scenarios, it attracted numerous attending experts to stop for consultations and engage in detailed discussions.
Report Sharing
At the Annual Conference of Pathology in Xinjiang, Professor Yang Lin, founder of Dipath and a faculty member at the School of Engineering, Westlake University, was invited to deliver a special report. He outlined the development trends of AI in pathology based on the current industry landscape, analyzed misconceptions surrounding digital transformation, and emphasized the practical implementation of digital and intelligent pathology.Uphold technological self-reliance and controllability, and deepen the integration of industry, academia, research, and healthcare; and propose a set of“Prompt+Know how”Human-Machine Collaboration Logic: Define work requirements through prompts, and complete AI interaction and result evaluation using know-how.
At the conclusion of his report, Professor Yang Lin leveraged this human-AI collaborative framework to produce a thematic short film using AI technology, authentically recreating the daily routine of pathologists:“8 p.m., and the lights in the pathology department are still on. Three hundred slides, countless cells—each one may hold the answer.”Day after day, pathologists continue to evaluate specimens with the naked eye, racing against time. The emergence of the AI assistant “Xiao Di” does not replace physicians in making diagnoses, but rather accurately captures key clues and shares the burden of repetitive tasks, achieving“You Think, She Sees”。
The short film offers a heartfelt message to all pathology professionals, wishing that every hardworking pathologist may enjoy a warm meal sooner and return to their personal lives earlier.
Meanwhile, at the 12th Hangzhou Breast Cancer Forum and Zhejiang Province Breast Cancer Screening Training Conference,Professor Feng Yun, Northwestern UniversityInvited to take the stage, presenting"Precision Subtyping of Breast Pathology Driven by Large Language Models"Frontier Topic Sharing. Currently, large language models have become the core driving force in the digital and intelligent transformation of pathology. Professor Feng Jun closely followed the frontier directions of the industry, combined with interdisciplinary research achievements, and engaged in in-depth discussions with breast pathology professionals present on the innovative implementation pathways of AI technology empowering early screening and precise subtyping of breast diseases, fully demonstratingLarge language models are comprehensively reshaping traditional pathology diagnosis paradigms, serving as a key breakthrough in driving the digital and intelligent transformation of the pathology industry.。
For years, Dipath has been deeply engaged in the field of digital and intelligent pathology, adhering to independent and controllable core technologies. Leveraging a multi-university industry-academia-research-medical collaboration platform, the company has developed digital and intelligent solutions tailored to the pathology departments of hospitals at all levels across China. This multi-regional academic showcase comprehensively demonstrated the company’s robust technological reserves and its nationwide clinical service capabilities.
Looking ahead, Dipath will continuously iterate and optimize its large pathology models and comprehensive suite of hardware and software products, empowering medical institutions across China to accelerate their digital and intelligent transformation in pathology. Working hand in hand with pathology professionals nationwide, Dipath is committed to steadily promoting the high-quality development of China’s digital and intelligent pathology industry.
Dipath, founded in 2017, has been deeply engaged in the field of AI and digital pathology for two decades. Upholding the mission of "Illuminating Pathology with Intelligence to Make Precision Medicine Accessible," it is a leading benchmark enterprise in China's digital-intelligent pathology and AI diagnostics sector. The company has received over 200 honors, including recognition as a National High-Tech Enterprise, a Zhejiang Province Specialized, Refined, Distinctive, and Innovative SME, a Hangzhou Quasi-Unicorn, and a Zhejiang Science and Technology New Dragon. Since being included among enterprises above designated size in 2023, its annual revenue growth rate has consistently remained above 70%, demonstrating strong momentum.
On January 6, 2026, Professor Yang Lin, founder of the company and a professor at the Laboratory for Artificial Intelligence and Biomedical Imaging at Westlake University, donated equity to Westlake University on behalf of the enterprise. This donation aims to deepen industry-academia-research-medical collaboration and promote high-quality development in medical-engineering interdisciplinary innovation and the digital-intelligent pathology industry.
Top-tier R&D Strength
With over 20 years of deep expertise in the field of pathology AI, Dipath has established R&D centers in Hangzhou, Shaanxi, and Guangdong. The company operates a High-Tech Enterprise R&D Center and a Postdoctoral Workstation, with R&D personnel comprising 60% of its workforce. Leveraging a deeply integrated industry-academia-research-medical model centered around Westlake University, Dipath has built a full-chain innovation system spanning from basic scientific research to clinical translation.Led over 40 national-level research foundation projects, published more than 500 high-impact SCI papers, with total citations exceeding 10,000.Full-Stack Independent Innovation
The company has established a product ecosystem built on its proprietary DeepPathAI multimodal pathology foundation model, utilizing a multi-agent collaborative architecture. This system covers comprehensive scenarios including cytology, histology, immunohistochemistry, molecular pathology, and translational research. The company holds over 220 intellectual property rights, including more than 80 invention patents, and has obtained 25 medical device registration certificates. It was selected as a winning entity in the AI Medical Device Innovation Challenge launched by the Ministry of Industry and Information Technology (MIIT) and the National Medical Products Administration (NMPA), leading efforts to overcome key technological bottlenecks in the industry.Full-Scenario Product Matrix
Powered by the DeepPathAI Shendi Mofang foundational large model, the company has developed a comprehensive digital-intelligent pathology product solution. Independently developed.Smart Cytology, Intelligent Pathology, Intelligent Cytology, Large Model Scanners, and other product series; integrated with cloud services such as remote consultation, pathology information management and quality control systems, intelligent residency training systems, and digital pathology cloud storage.Large-Scale Clinical Implementation
The company has served over 1,500 medical institutions, research organizations, and pharmaceutical companies worldwide. It has partnered with domestic Grade A tertiary hospitals to co-establish nearly 100 fully digital and intelligent pathology departments, and jointly launched several specialty-specific large pathology models, comprehensively enhancing the integrated capabilities in pathological diagnosis, education, and research. In terms of teleconsultation and educational empowerment, it has facilitated over 20,000 live microscopic teaching sessions and more than 30,000 real-time microscopic consultations and remote diagnostic sessions, covering thousands of hospitals across China.Dipath · Global Talent Recruitment
Westlake University Yang Lin Lab · PhD Recruitment